Advertisement
Advertisement
GLMD
Galmed Pharmaceuticals Ltd.
0.60
USDSponsored
+0.02
+3.57%
Mar 25, 15:32 UTC -4
Closed
Pre-Market
0.61
+0.01
+1.67%
GLMD Earnings Reports
Positive Surprise Ratio
GLMD beat 23 of 36 last estimates.
64%
Next Report
Next Week
Date of Next Report
Mar 31, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.52
Implied change from Q3 25 (Revenue/ EPS)
--
/+57.58%
Implied change from Q4 24 (Revenue/ EPS)
--
/--
Galmed Pharmaceuticals Ltd. earnings per share and revenue
On Nov 26, 2025, GLMD reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 40.09% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +12.40% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an increase of 57.58% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Galmed Pharmaceuticals Ltd.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Galmed Pharmaceuticals Ltd. reported EPS of -$0.33, beating estimates by 40.09%, and revenue of $0.00, -- -- expectations.
How did the market react to Galmed Pharmaceuticals Ltd.'s Q3 2025 earnings?
The stock price moved up 12.4%, changed from $0.82 before the earnings release to $0.92 the day after.
When is Galmed Pharmaceuticals Ltd. expected to report next?
The next earning report is scheduled for Mar 31, 2026.
What are the forecasts for Galmed Pharmaceuticals Ltd.'s next earnings report?
Based on 3
analysts, Galmed Pharmaceuticals Ltd. is expected to report EPS of -$0.52 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement